We gave full play to the resource advantages of our department and treated 32 patients with ruptured esophagogastric varices combined with hepatocellular carcinoma by endoscopic intervention (ligature, sclerosis, tissue glue adhesion) and radiographic intervention (transhepatic artery embolization chemotherapy), and received good results, one case is reported below. Liu Changjiang, Department of Gastroenterology, General Hospital of Jinan Military Region A male, 49 years old, was admitted to hospital with vomiting blood and blood in stool for 1 day. On admission: clear consciousness, poor spirit, anemic appearance. Blood pressure was 85/55 mmHg, heart rate was 115 beats/min, the rate was uniform, and no pathological murmur was heard. There was no significant abnormality in pulmonary examination, abdominal tenderness, epigastric pressure pain, no rebound pain. The liver and spleen were not detected under the ribs, the mobile turbid sounds were negative, and the bowel sounds were active. A small amount of dark red stool was intermittently formed after admission. The hemoglobin was 65g/L, liver function ALT66/U, AST78U/L, ALB28.3g/L. AFP780IU/L coagulation test: PT16.3s, PTA51%. After admission, he was treated with volume expansion, portal pressure reduction, hepatoprotection, red blood cell concentrate infusion, etc. He was also treated with endoscopy and saw esophageal varices (severe) and 2 mass varices in the gastric fundus, which were treated endoscopically with 2 sets of esophageal varices ligated with 12 balls and 3 ml of tissue adhesive injected into the varices in the gastric fundus. CT examination was performed 3 days after treatment, and a hepatocellular carcinoma measuring about 2.0cm×1.5cm was seen in the right lobe of the liver near the top of the diaphragm. On the 5th day of hospitalization, he was treated with transhepatic artery embolization chemotherapy and was discharged from the hospital in 13 days. After discharge, there was no further gastrointestinal bleeding, and after 1 month, gastroscopy showed that the varices in the esophagogastric fundus had basically disappeared. The repeat CT showed that the hepatocellular carcinoma lesion disappeared, the iodine oil deposition was good, and the AFP test was normal. Discussion: Portal hypertension and esophagogastric fundic variceal bleeding is a common emergency in gastroenterology, with a dangerous condition. Our portal hypertension is mainly caused by cirrhosis, which is not only easily complicated by esophagogastric varices but also by hepatocellular carcinoma. In patients with cirrhosis, the annual incidence of liver cancer is 3-5%, which is much higher than the chances of developing liver cancer in normal people. Conventional treatment of esophagogastric fundic variceal bleeding includes restoration of blood volume, application of drugs to reduce portal pressure and other drugs and balloon compression to stop bleeding, but these treatments only stop bleeding temporarily and it is still easy to bleed after bleeding stops. Surgical treatment such as splenectomy and fundoplication with high risk and high mortality in emergency, and the number of surgical treatment cases has decreased significantly in recent years. How to control ruptured esophagogastric variceal bleeding and prevent rebleeding has become an important issue in medical treatment. Surgical treatment occupies an important position in the treatment of hepatocellular carcinoma, but the role of surgical resection has certain limits because: (1) hepatocellular carcinoma is highly malignant and highly susceptible to intrahepatic dissemination and metastasis; (2) primary hepatocellular carcinoma in China is mostly accompanied by severe cirrhosis and often has liver function loss; (3) a significant proportion of primary hepatocellular carcinoma occurs in multiple centers; and (4) patients are often in the middle and late stages when they are diagnosed. Therefore, low resection rates and high recurrence rates are key constraints to the surgical treatment of hepatocellular carcinoma. The guidelines for the treatment of hepatocellular carcinoma issued by the American Veterans Affairs Hepatitis C Y Source Center (HCRC) in 2009 state that patients with hepatocellular carcinoma who have portal hypertension (hepatic portal pressure gradient >10 mmHg) or total bilirubin >1.5 mg/mL are not suitable for surgical treatment, regardless of tumor size. In recent years, comprehensive treatment with optimal combination of surgical treatment and various non-surgical treatment methods has been increasingly developed as a new way to further improve the efficacy of liver cancer. Interventional therapy is the preferred non-surgical treatment method, and the most important means of radio-interventional treatment for liver cancer is hepatic artery chemoembolization. For hepatocellular carcinoma that cannot be resected radically, the preferred non-surgical treatment method is hepatic artery chemoembolization. Therefore, for cirrhotic esophagogastric varices ruptured and bleeding combined with hepatocellular carcinoma, endoscopic treatment combined with hepatic artery embolization chemotherapy is the best treatment option.